SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin rises on launching generic Clobetasol Propionate Ointment in US

10 Oct 2018 Evaluate

Lupin is currently trading at Rs. 876.25, up by 10.75 points or 1.24% from its previous closing of Rs. 865.50 on the BSE.

The scrip opened at Rs. 875.00 and has touched a high and low of Rs. 884.45 and Rs. 870.00 respectively. So far 43430 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1090.00 on 30-Oct-2017 and a 52 week low of Rs. 723.55 on 15-May-2018.

Last one week high and low of the scrip stood at Rs. 895.00 and Rs. 818.90 respectively. The current market cap of the company is Rs. 39795.30 crore.

The promoters holding in the company stood at 47.01%, while Institutions and Non-Institutions held 37.89% and 15.10% respectively.

Lupin has launched Clobetasol Propionate Ointment USP 0.05%, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Clobetasol Propionate Ointment USP 0.05% had annual sales of around $93.4 million in the US (IQVIA MAT June 2018).

The company’s Clobetasol Propionate Ointment USP, 0.05% is the generic equivalent of Fougera Pharmaceuticals Inc.’s Temovate Ointment, 0.05%. It is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2324.25 -2.25 (-0.10%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×